Insmed (LTS:0JAV) Margin of Safety % (DCF Dividends Based): N/A (As of Aug. 05, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0JAV Insmed Inc LTS:0JAV
66 GF Score
Price $100.27
GF Value $185.40
Valuation Possible Value Trap
! 4 Warning Signs
View Full Analysis

What is Insmed Margin of Safety % (DCF Dividends Based)?

Margin of Safety % (DCF Dividends Based) = (Intrinsic Value: DCF (Dividends Based) - Current Price) / Intrinsic Value: DCF (Dividends Based).

Note: Discounted Dividend model is only suitable for companies who have a consistant distribution history with more than 5 years. If the company's dividends does not remain steady over a long period, results may not be accurate due to the low consistency. The model is also only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, the data will not be stored into our database.

Insmed's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Dividends Based) is not calculated.

LTS:0JAV vs INCY, BNTX, MRNA: Margin of Safety % (DCF Dividends Based) Comparison

For the Biotechnology subindustry, Insmed's Margin of Safety % (DCF Dividends Based), along with its competitors' market caps and Margin of Safety % (DCF Dividends Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Insmed Margin of Safety % (DCF Dividends Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Insmed's Margin of Safety % (DCF Dividends Based) distribution charts can be found below:

* The bar in red indicates where Insmed's Margin of Safety % (DCF Dividends Based) falls into.


LTS:0JAV
66GF Score
Insmed Inc LTS:0JAV
Margin of Safety % (DCF Dividends Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Insmed (LTS:0JAV) Overvalued in 2026?

Based on GuruFocus' analysis, Insmed stock appears to be undervalued. The current stock price of $100.27 is trading 45.9% below its estimated GF Value™ of $185.40. GuruFocus considers Insmed to be Possible Value Trap.

Key valuation signals for LTS:0JAV:

  • Margin of Safety % (DCF Dividends Based): N/A
  • GF Value™: $185.40 vs. price of $100.27 (45.9% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the LTS:0JAV stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Insmed Business Description

Address 700 US Highway 202/206, Bridgewater, NJ, USA, 08807
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
66GF Score

Get the complete analysis for LTS:0JAV

Margin of Safety % (DCF Dividends Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$100.27
Price
$185.40
GF Value